Your browser doesn't support javascript.
loading
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Dummer, Reinhard; Brase, Jan C; Garrett, James; Campbell, Catarina D; Gasal, Eduard; Squires, Matthew; Gusenleitner, Daniel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Flaherty, Keith; Larkin, James; Robert, Caroline; Kefford, Richard; Kirkwood, John M; Hauschild, Axel; Schadendorf, Dirk; Long, Georgina V.
Afiliação
  • Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Electronic address: reinhard.dummer@usz.ch.
  • Brase JC; Novartis Pharma, Basel, Switzerland.
  • Garrett J; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Campbell CD; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Gasal E; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Squires M; Novartis Pharma, Basel, Switzerland.
  • Gusenleitner D; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
  • Santinami M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Atkinson V; Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane, QLD, Australia.
  • Mandalà M; Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy.
  • Chiarion-Sileni V; Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
  • Flaherty K; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Larkin J; Royal Marsden NHS Foundation Trust, London, UK.
  • Robert C; Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France.
  • Kefford R; Macquarie University and Westmead Hospital, Sydney, NSW, Australia; Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia.
  • Kirkwood JM; Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
  • Hauschild A; University Hospital Schleswig-Holstein, Kiel, Germany.
  • Schadendorf D; University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
  • Long GV; Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
Lancet Oncol ; 21(3): 358-372, 2020 03.
Article em En | MEDLINE | ID: mdl-32007138
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pele Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas B-raf / Melanoma / Mutação / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Pele Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Medicamentos Antineoplásicos / Proteínas Proto-Oncogênicas B-raf / Melanoma / Mutação / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article